{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:48:27Z","timestamp":1778924907660,"version":"3.51.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010201","name":"Department of Science and Technology, Government of Rajasthan","doi-asserted-by":"publisher","award":["EMR\/2017\/003880"],"award-info":[{"award-number":["EMR\/2017\/003880"]}],"id":[{"id":"10.13039\/501100010201","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010201","name":"Department of Science and Technology, Government of Rajasthan","doi-asserted-by":"publisher","award":["CRG\/2021\/004281"],"award-info":[{"award-number":["CRG\/2021\/004281"]}],"id":[{"id":"10.13039\/501100010201","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00277-024-05742-8","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T04:02:20Z","timestamp":1713326540000},"page":"1919-1929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia"],"prefix":"10.1007","volume":"103","author":[{"given":"Daniel Zechariah Paul","family":"Jebanesan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raveen Stephen Stallon","family":"Illangeswaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharathi M.","family":"Rajamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakhi Thalayattu","family":"Vidhyadharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saswati","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayanthara K.","family":"Bijukumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balaji","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaji R.","family":"Velayudhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9443-439X","authenticated-orcid":false,"given":"Poonkuzhali","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"5742_CR1","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/sj.leu.2403480","volume":"18","author":"B George","year":"2004","unstructured":"George B et al (2004) Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia 18:1587\u20131590","journal-title":"Leukemia"},{"key":"5742_CR2","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood-2005-08-3532","volume":"107","author":"V Mathews","year":"2006","unstructured":"Mathews V et al (2006) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107:2627\u20132632","journal-title":"Blood"},{"key":"5742_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ajh.10138","volume":"70","author":"V Mathews","year":"2002","unstructured":"Mathews V et al (2002) Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol 70:292\u2013299","journal-title":"Am J Hematol"},{"key":"5742_CR4","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1200\/JCO.2010.28.5031","volume":"28","author":"V Mathews","year":"2010","unstructured":"Mathews V et al (2010) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol Off J Am Soc Clin Oncol 28:3866\u20133871","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5742_CR5","first-page":"248","volume":"70","author":"J Hu","year":"1999","unstructured":"Hu J et al (1999) Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. Int J Hematol 70:248\u2013260","journal-title":"Int J Hematol"},{"key":"5742_CR6","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJM199811053391901","volume":"339","author":"SL Soignet","year":"1998","unstructured":"Soignet SL et al (1998) Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide. N Engl J Med 339:1341\u20131348","journal-title":"N Engl J Med"},{"key":"5742_CR7","doi-asserted-by":"publisher","first-page":"eaan1011","DOI":"10.1126\/scisignal.aan1011","volume":"10","author":"H Niu","year":"2017","unstructured":"Niu H et al (2017) Endogenous Retinoid X Receptor ligands in mouse hematopoietic cells. Sci Signal 10:eaan1011","journal-title":"Sci Signal"},{"key":"5742_CR8","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1182\/blood-2009-07-230805","volume":"115","author":"J Zhou","year":"2010","unstructured":"Zhou J et al (2010) Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood 115:1697\u20131702","journal-title":"Blood"},{"key":"5742_CR9","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.leukres.2003.12.012","volume":"28","author":"S Parmar","year":"2004","unstructured":"Parmar S et al (2004) Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and\/or newly diagnosed patients at least 65 years old. Leuk Res 28:909\u2013919","journal-title":"Leuk Res"},{"key":"5742_CR10","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2011.59","volume":"25","author":"AK Burnett","year":"2011","unstructured":"Burnett AK et al (2011) The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia 25:1122\u20131127","journal-title":"Leukemia"},{"key":"5742_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/ajh.22092","volume":"86","author":"JS Welch","year":"2011","unstructured":"Welch JS et al (2011) Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Am J Hematol 86:796\u2013800","journal-title":"Am J Hematol"},{"key":"5742_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1046\/j.0007-1048.2001.03298.x","volume":"116","author":"MT Rojewski","year":"2002","unstructured":"Rojewski MT, Baldus C, Knauf W, Thiel E, Schrezenmeier H (2002) Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br J Haematol 116:555\u2013563","journal-title":"Br J Haematol"},{"key":"5742_CR13","doi-asserted-by":"publisher","first-page":"32550","DOI":"10.18632\/oncotarget.15925","volume":"8","author":"NI Noguera","year":"2017","unstructured":"Noguera NI et al (2017) High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro. Oncotarget 8:32550\u201332565","journal-title":"Oncotarget"},{"key":"5742_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00277-013-1821-2","volume":"93","author":"A Abraham","year":"2014","unstructured":"Abraham A et al (2014) ABCB6 RNA expression in leukemias\u2013expression is low in acute promyelocytic leukemia and FLT3-ITD-positive acute myeloid leukemia. Ann Hematol 93:509\u2013512","journal-title":"Ann Hematol"},{"key":"5742_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2217\/pgs-2016-0150","volume":"18","author":"S Varatharajan","year":"2017","unstructured":"Varatharajan S et al (2017) ATP-binding casette transporter expression in acute myeloid leukemia: association with in vitro cytotoxicity and prognostic markers. Pharmacogenomics 18:235\u2013244","journal-title":"Pharmacogenomics"},{"key":"5742_CR16","doi-asserted-by":"publisher","first-page":"32885","DOI":"10.18632\/oncotarget.25972","volume":"9","author":"K Nagai","year":"2018","unstructured":"Nagai K et al (2018) Combination of ATO with FLT3 TKIs eliminates FLT3\/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885\u201332899","journal-title":"Oncotarget"},{"key":"5742_CR17","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1080\/10428194.2020.1775212","volume":"61","author":"C Liang","year":"2020","unstructured":"Liang C et al (2020) Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD. Leuk Lymphoma 61:2692\u20132699","journal-title":"Leuk Lymphoma"},{"key":"5742_CR18","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.7150\/jca.29751","volume":"11","author":"X-J Liu","year":"2020","unstructured":"Liu X-J et al (2020) Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells. J Cancer 11:3476\u20133482","journal-title":"J Cancer"},{"key":"5742_CR19","first-page":"1254","volume":"130","author":"S Karathedath","year":"2017","unstructured":"Karathedath S et al (2017) Molecular and Pharmacological Inhibition of ATP Binding Cassette Transporter ABCB6 Decreases Chemoresistance in Acute Myeloid Leukemia. Blood 130:1254","journal-title":"Blood"},{"key":"5742_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40164-023-00411-4","volume":"12","author":"X Liu","year":"2023","unstructured":"Liu X et al (2023) Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis. Exp Hematol Oncol 12:47","journal-title":"Exp Hematol Oncol"},{"key":"5742_CR21","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.molmed.2016.05.002","volume":"22","author":"S Menegon","year":"2016","unstructured":"Menegon S, Columbano A, Giordano S (2016) The Dual Roles of NRF2 in Cancer. Trends Mol Med 22:578\u2013593","journal-title":"Trends Mol Med"},{"key":"5742_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","volume":"34","author":"M Rojo de la Vega","year":"2018","unstructured":"Rojo de la Vega M, Chapman E, Zhang DD (2018) NRF2 and the Hallmarks of Cancer. Cancer Cell 34:21\u201343","journal-title":"Cancer Cell"},{"key":"5742_CR23","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/cam4.2101","volume":"8","author":"S Wu","year":"2019","unstructured":"Wu S, Lu H, Bai Y (2019) Nrf2 in cancers: A double-edged sword. Cancer Med 8:2252\u20132267","journal-title":"Cancer Med"},{"key":"5742_CR24","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/carcin\/bgn095","volume":"29","author":"X-J Wang","year":"2008","unstructured":"Wang X-J et al (2008) Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29:1235\u20131243","journal-title":"Carcinogenesis"},{"key":"5742_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3324\/haematol.2018.197749","volume":"104","author":"P Lin","year":"2019","unstructured":"Lin P et al (2019) The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes. Haematologica 104:485\u2013496","journal-title":"Haematologica"},{"key":"5742_CR26","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.3390\/ijms20184366","volume":"20","author":"HG Kim","year":"2019","unstructured":"Kim HG et al (2019) Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer. Int J Mol Sci 20:4366","journal-title":"Int J Mol Sci"},{"key":"5742_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.canlet.2017.10.005","volume":"412","author":"Y Sun","year":"2018","unstructured":"Sun Y, Abdul Aziz A, Bowles K, Rushworth S (2018) High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma. Cancer Lett 412:37\u201345","journal-title":"Cancer Lett"},{"key":"5742_CR28","doi-asserted-by":"publisher","first-page":"2360427","DOI":"10.1155\/2018\/2360427","volume":"2018","author":"Y Xiang","year":"2018","unstructured":"Xiang Y et al (2018) Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway. Oxid Med Cell Longev 2018:2360427","journal-title":"Oxid Med Cell Longev"},{"key":"5742_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41419-018-0340-4","volume":"9","author":"R Khamari","year":"2018","unstructured":"Khamari R et al (2018) Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors. Cell Death Dis 9:325","journal-title":"Cell Death Dis"},{"key":"5742_CR30","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/cas.13537","volume":"109","author":"H Kitamura","year":"2018","unstructured":"Kitamura H, Motohashi H (2018) NRF2 addiction in cancer cells. Cancer Sci 109:900\u2013911","journal-title":"Cancer Sci"},{"key":"5742_CR31","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.freeradbiomed.2018.10.426","volume":"129","author":"D Shin","year":"2018","unstructured":"Shin D, Kim EH, Lee J, Roh J-L (2018) Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic Biol Med 129:454\u2013462","journal-title":"Free Radic Biol Med"},{"key":"5742_CR32","doi-asserted-by":"publisher","first-page":"17639","DOI":"10.1038\/s41598-019-54065-6","volume":"9","author":"MM Silva","year":"2019","unstructured":"Silva MM, Rocha CRR, Kinker GS, Pelegrini AL, Menck CFM (2019) The balance between NRF2\/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells. Sci Rep 9:17639","journal-title":"Sci Rep"},{"key":"5742_CR33","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1158\/1078-0432.CCR-20-1985","volume":"27","author":"A Singh","year":"2021","unstructured":"Singh A et al (2021) NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes. Clin. Cancer Res. Off J Am Assoc Cancer Res 27:877\u2013888","journal-title":"Off J Am Assoc Cancer Res"},{"key":"5742_CR34","doi-asserted-by":"publisher","first-page":"111652","DOI":"10.1016\/j.biopha.2021.111652","volume":"142","author":"C Cheng","year":"2021","unstructured":"Cheng C et al (2021) Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C. Biomed Pharmacother Biomedecine Pharmacother 142:111652","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"5742_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/jb\/mvab025","volume":"170","author":"S Endo","year":"2021","unstructured":"Endo S et al (2021) Targeting Nrf2-antioxidant signalling reverses acquired cabazitaxel resistance in prostate cancer cells. J Biochem (Tokyo) 170:89\u201396","journal-title":"J Biochem (Tokyo)"},{"key":"5742_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41419-020-03319-7","volume":"12","author":"A K\u00fcper","year":"2021","unstructured":"K\u00fcper A et al (2021) Overcoming hypoxia-induced resistance of pancreatic and lung tumor cells by disrupting the PERK-NRF2-HIF-axis. Cell Death Dis 12:82","journal-title":"Cell Death Dis"},{"key":"5742_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semcancer.2021.06.003","volume":"76","author":"J Sivinski","year":"2021","unstructured":"Sivinski J, Zhang DD, Chapman E (2021) Targeting NRF2 to treat cancer. Semin Cancer Biol 76:61\u201373","journal-title":"Semin Cancer Biol"},{"key":"5742_CR38","doi-asserted-by":"publisher","first-page":"720076","DOI":"10.3389\/fphar.2022.720076","volume":"13","author":"H Kumar","year":"2022","unstructured":"Kumar H, Kumar RM, Bhattacharjee D, Somanna P, Jain V (2022) Role of Nrf2 Signaling Cascade in Breast Cancer: Strategies and Treatment. Front Pharmacol 13:720076","journal-title":"Front Pharmacol"},{"key":"5742_CR39","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3390\/antiox11040717","volume":"11","author":"S Kannan","year":"2022","unstructured":"Kannan S et al (2022) Targeting the NRF2\/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy. Antioxid Basel Switz 11:717","journal-title":"Antioxid Basel Switz"},{"key":"5742_CR40","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/mc.21921","volume":"52","author":"Y Zhong","year":"2013","unstructured":"Zhong Y et al (2013) Drug resistance associates with activation of Nrf2 in MCF-7\/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response. Mol Carcinog 52:824\u2013834","journal-title":"Mol Carcinog"},{"key":"5742_CR41","doi-asserted-by":"publisher","unstructured":"Park SH et al. (2018) Resistance to gefitinib and cross-resistance to irreversible EGFR-TKIs mediated by disruption of the Keap1-Nrf2 pathway in human lung cancer cells. FASEB J Off Publ Fed Am Soc Exp Biol. fj201800011R.\u00a0\u00a0https:\/\/doi.org\/10.1096\/fj.201800011R.","DOI":"10.1096\/fj.201800011R"},{"key":"5742_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1755-8794-3-37","volume":"3","author":"Q Liu","year":"2010","unstructured":"Liu Q et al (2010) The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics 3:37","journal-title":"BMC Med Genomics"},{"key":"5742_CR43","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","volume":"11","author":"A Singh","year":"2016","unstructured":"Singh A et al (2016) Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. ACS Chem Biol 11:3214\u20133225","journal-title":"ACS Chem Biol"},{"key":"5742_CR44","doi-asserted-by":"publisher","first-page":"8592348","DOI":"10.1155\/2019\/8592348","volume":"2019","author":"E Panieri","year":"2019","unstructured":"Panieri E, Saso L (2019) Potential Applications of NRF2 Inhibitors in Cancer Therapy. Oxid Med Cell Longev 2019:8592348","journal-title":"Oxid Med Cell Longev"},{"key":"5742_CR45","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.canlet.2020.01.010","volume":"474","author":"Y Zhou","year":"2020","unstructured":"Zhou Y et al (2020) Flumethasone enhances the efficacy of chemotherapeutic drugs in lung cancer by inhibiting Nrf2 signaling pathway. Cancer Lett 474:94\u2013105","journal-title":"Cancer Lett"},{"key":"5742_CR46","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1038\/onc.2017.153","volume":"36","author":"E-J Choi","year":"2017","unstructured":"Choi E-J et al (2017) A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer. Oncogene 36:5285\u20135295","journal-title":"Oncogene"},{"key":"5742_CR47","doi-asserted-by":"publisher","first-page":"101131","DOI":"10.1016\/j.redox.2019.101131","volume":"22","author":"Y Zhou","year":"2019","unstructured":"Zhou Y et al (2019) Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway. Redox Biol 22:101131","journal-title":"Redox Biol"},{"key":"5742_CR48","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41408-018-0087-2","volume":"8","author":"I Laverdi\u00e8re","year":"2018","unstructured":"Laverdi\u00e8re I et al (2018) Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia. Blood Cancer J 8:52","journal-title":"Blood Cancer J"},{"key":"5742_CR49","doi-asserted-by":"publisher","first-page":"107054","DOI":"10.1016\/j.leukres.2023.107054","volume":"128","author":"RSS Illangeswaran","year":"2023","unstructured":"Illangeswaran RSS et al (2023) Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines. Leuk Res 128:107054","journal-title":"Leuk Res"},{"key":"5742_CR50","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski A, He L, Aittokallio T, Tang J (2017) SynergyFinder: a web application for analyzing drug combination dose\u2013response matrix data. Bioinformatics 33:2413\u20132415","journal-title":"Bioinformatics"},{"key":"5742_CR51","doi-asserted-by":"publisher","first-page":"e0177227","DOI":"10.1371\/journal.pone.0177227","volume":"12","author":"S Karathedath","year":"2017","unstructured":"Karathedath S et al (2017) Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. PLoS ONE 12:e0177227","journal-title":"PLoS ONE"},{"key":"5742_CR52","doi-asserted-by":"crossref","unstructured":"Singh A et al. (2006) Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med\u00a03","DOI":"10.1371\/journal.pmed.0030420"},{"key":"5742_CR53","doi-asserted-by":"publisher","first-page":"6568","DOI":"10.3390\/ijms23126568","volume":"23","author":"DH Hoang","year":"2022","unstructured":"Hoang DH et al (2022) Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation. Int J Mol Sci 23:6568","journal-title":"Int J Mol Sci"},{"key":"5742_CR54","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1073\/pnas.1014275108","volume":"108","author":"D Ren","year":"2011","unstructured":"Ren D et al (2011) Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A 108:1433\u20131438","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5742_CR55","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.freeradbiomed.2011.03.008","volume":"50","author":"X Tang","year":"2011","unstructured":"Tang X et al (2011) Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2\/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med 50:1599\u20131609","journal-title":"Free Radic Biol Med"},{"key":"5742_CR56","doi-asserted-by":"publisher","first-page":"33761","DOI":"10.1074\/jbc.M604748200","volume":"281","author":"M-H Kweon","year":"2006","unstructured":"Kweon M-H, Adhami VM, Lee J-S, Mukhtar H (2006) Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J Biol Chem 281:33761\u201333772","journal-title":"J Biol Chem"},{"key":"5742_CR57","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1128\/MCB.01204-10","volume":"31","author":"P Rada","year":"2011","unstructured":"Rada P et al (2011) SCF\/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol 31:1121\u20131133","journal-title":"Mol Cell Biol"},{"key":"5742_CR58","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/carcin\/bgr259","volume":"33","author":"I Almazari","year":"2012","unstructured":"Almazari I et al (2012) Guggulsterone induces heme oxygenase-1 expression through activation of Nrf2 in human mammary epithelial cells: PTEN as a putative target. Carcinogenesis 33:368\u2013376","journal-title":"Carcinogenesis"},{"key":"5742_CR59","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1038\/onc.2012.388","volume":"32","author":"S Chowdhry","year":"2013","unstructured":"Chowdhry S et al (2013) Nrf2 is controlled by two distinct \u03b2-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32:3765\u20133781","journal-title":"Oncogene"},{"key":"5742_CR60","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/ncb3341","volume":"18","author":"EC Lien","year":"2016","unstructured":"Lien EC et al (2016) Glutathione biosynthesis is a metabolic vulnerability in PI(3)K\/Akt-driven breast cancer. Nat Cell Biol 18:572\u2013578","journal-title":"Nat Cell Biol"},{"key":"5742_CR61","doi-asserted-by":"publisher","first-page":"29721","DOI":"10.1038\/srep29721","volume":"6","author":"N Kim","year":"2016","unstructured":"Kim N et al (2016) Cardiac glycosides display selective efficacy for STK11 mutant lung cancer. Scintific reports 6:29721","journal-title":"Scintific reports"},{"key":"5742_CR62","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1038\/s41467-019-12888-x","volume":"10","author":"FT Martinez","year":"2019","unstructured":"Martinez FT et al (2019) Identification and characterization of Cardiac Glycosides as senolytic compounds. Nat Commun 10:4731","journal-title":"Nat Commun"},{"key":"5742_CR63","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/15384047.2018.1504723","volume":"20","author":"K Deng","year":"2019","unstructured":"Deng K et al (2019) Sodium chloride (NaCl) potentiates digoxin-induced anti-tumor activity in small cell lung cancer. Cancer Biol Ther 20:52\u201364","journal-title":"Cancer Biol Ther"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05742-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05742-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05742-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T07:08:17Z","timestamp":1715584097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05742-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["5742"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05742-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,17]]},"assertion":[{"value":"4 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any competing interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}